Abvc Biopharma (ABVC) Income from Continuing Operations (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Income from Continuing Operations came in at 1335050.0 in Q1 2026, down 78.93% YoY from 6337036.99 in Q1 2025, and up 55.74% on a QoQ basis from 3016463.0 in Q4 2025.
Abvc Biopharma (ABVC) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Income from Continuing Operations data on file, last reported at 1335050.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 78.93% year-over-year to 1335050.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8767819.0 (down 184.9% YoY) and the FY2025 annual result came in at 8376959.0, down 59.29% from the prior year.
- Income from Continuing Operations grew to 1335050.0 in Q1 2026, from 3016463.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 487431.0 in Q3 2024 to a low of 6087615.0 in Q1 2022.
- A 5-year average of 2305852.76 and a median of 2083473.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 409.29% — and 2024, when it surged 85.53%.
- Tracing ABVC's Income from Continuing Operations over 5 years: stood at 4334206.0 in 2022, then soared by 83.84% to 700309.0 in 2023, then fell by 13.74% to 796527.0 in 2024, then plunged by 278.7% to 3016463.0 in 2025, then soared by 55.74% to 1335050.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1335050.0 (Q1 2026), 3016463.0 (Q4 2025), and 2083473.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -640,280.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -640,280.00 |
| Mar 31, 2026 | -1.34 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -2.08 Mn |
| Jun 30, 2025 | -2.33 Mn |
| Mar 31, 2025 | -746,119.00 |
| Dec 31, 2024 | -796,527.00 |
| Sep 30, 2024 | -487,431.00 |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -700,309.00 |
| Sep 30, 2023 | -3.37 Mn |
| Jun 30, 2023 | -2.32 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | -4.33 Mn |
| Sep 30, 2022 | -3.78 Mn |
| Jun 30, 2022 | -1.95 Mn |
| Mar 31, 2022 | -6.09 Mn |
| Dec 31, 2021 | -6.90 Mn |
| Sep 30, 2021 | -1.89 Mn |